Covid: Xenothera hopes their Xav-19 therapy can be marketed from early 2022

Published by Laurent P. · Updated on 19 November 2021 at 11h36 · Published on 19 November 2021 at 10h19
And what if, amid the fight against Covid, one could rely – in addition to the upcoming vaccine – on antibody-based treatments? After Bamlanivimab – the treatment developed by the Eli Lilly laboratory – or even Regeneron, this is now French Nantes-based laboratory Xenothera’s turn to present a treatment undergoing clinical trials, Xav-19. The therapy is waiting for the green light for marketing from early 2022.

Good news amid the fight against Covid… After Bamlanivimab – developed by the Eli Lilly laboratory – or even Regeneron – by the eponymous pharmaceutical company – Nantes-based laboratory Xenothera has announced they have come up with an antibody-based treatment. Called Xav-19, it is based on “polyclonal” antibodies, different from the “monoclonal” antibodies addressing the virus from one side, as the others do some from all sides at the same time, as Xenothera CEO Odile Duvaux explains. A molecule which clinical trials have entered the third phase: "Our product is now in phase 3 of the clinical trials. If everything goes well, it could be approved and used from this Fall", Duvaux said this Wednesday August 18, 2021 to our peers from Le Monde.

According to our peers from Ouest France, this treatment is based on polyclonal antibodies produced by “‘glyco-humanized’ pigs (genetically modified)” for an immune response similar to the one produced by human. It is part of a clinical trial, Polycor, that started in the Summer 2020, and through the study, it has been first inoculated to 10 patients from four different hospitals, and then 10 others, the idea being to show the product does not cause side-effects. A clinical trial that is still going on: “A wider trial is expected to begin by two to three weeks, on 400 patients. Forty hospitals in France are to be part of it” Professor François Raffi, Head of the Infectiology Department of the Nantes University Hospital said.

A treatment that could also be subject to another clinical trial outside the country. As for a possible issuing, if clinical trials make it to the end and meet encouraging results, it could take place in the Spring 2021, for “temporary use” as said by Odile Duvaux. She went on: “Xav-19 is a matter of national sovereignty”. And for good reason, the stakes are high since this treatment is to be made available for as many people as possible, in contrast to the one developed by Regeneron, far more expensive to produce. However, Xav-19is intended for patients infected by the virus for seven to ten days and hospitalized and therefore in a serious conditionProfessor Raffi went on. Good hope then to limit the death toll caused by severe cases.

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search